Cargando…
Enzobiotics—A Novel Therapy for the Elimination of Uremic Toxins in Patients with CKD (EETOX Study): A Multicenter Double-Blind Randomized Controlled Trial
Design, participants, setting, and measurements: Predialysis adult participants with chronic kidney disease (CKD) and mean estimated glomerular filtration rate (eGFR) <45 mL/min per 1.73 m(2)) were recruited in 2019 to a multicentric double-blinded randomized controlled trial of enzobiotic therap...
Autores principales: | Saxena, Anita, Srinivasa, Sanjay, Veerappan, Ilangovan, Jacob, Chakko, Mahaldar, Amol, Gupta, Amit, Rajagopal, Ananthasubramaniam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503043/ https://www.ncbi.nlm.nih.gov/pubmed/36145188 http://dx.doi.org/10.3390/nu14183804 |
Ejemplares similares
-
The Impact of CKD on Uremic Toxins and Gut Microbiota
por: Rysz, Jacek, et al.
Publicado: (2021) -
The AKI-to-CKD Transition: The Role of Uremic Toxins
por: André, Camille, et al.
Publicado: (2023) -
Uremic Toxins and Their Relation with Oxidative Stress Induced in Patients with CKD
por: Pieniazek, Anna, et al.
Publicado: (2021) -
Decreasing microbiota-derived uremic toxins to improve CKD outcomes
por: Beker, Braian M, et al.
Publicado: (2022) -
Uremic Toxins and Protein-Bound Therapeutics in AKI and CKD: Up-to-Date Evidence
por: Chen, Jia-Huang, et al.
Publicado: (2021)